Researchers at Brown University disclosed a molecular mechanism that could enhance therapeutic responses in glioblastoma, offering a potential pathway to overcome intratumoral resistance, the team reported in Cell Reports. The study identified specific targets within tumor microenvironments that modulate treatment sensitivity and immune engagement. Authors provided functional data linking the pathway to therapy resistance in organoid and in vivo models, and proposed combination strategies to exploit vulnerabilities. The work bridges tumor biology insights with translational options for antibody‑drug conjugates and immune-modulating therapies. The findings create a preclinical rationale for testing targeted combinations in glioblastoma trials and for incorporating the identified biomarkers into patient-selection frameworks for next‑generation therapeutics.